Crescent Biopharma, Inc. (CBIO) Stock

Crescent Biopharma, Inc. (CBIO) is a Healthcare stock trading at $17.19 (as of 2026-08-21), with a market capitalization of $638.50M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates. Its pipeline includes oncology antibodies such as CR-001, along with CR-002 and CR-003, and it works with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on development and commercialization of oncology therapeutics.

Understand Crescent Biopharma, Inc.: how it makes money

Crescent Biopharma researches and develops cancer therapy candidates, including CR-001 and other pipeline programs, and it also works through an oncology strategic partnership with Sichuan Kelun-Biotech for development and commercialization, with money coming from collaborations and licensing agreements.

The company is pre-commercial, so its near-term profit model depends on any future collaboration and licensing economics rather than product sales revenue.

Revenue by segment (latest quarter)
Collab/Lic$0.0B

Business quality (Weak): Latest-quarter revenue is 0.0B, so the key validation path is clinical progress in the pipeline and traction within collaboration and commercialization efforts.

Bull case

  • Defined oncology pipeline: The pipeline includes CR-001 (an anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors) plus CR-002 and CR-003.
  • Strategic development and commercialization partnership: Crescent has a strategic partnership with Sichuan Kelun-Biotech for development and commercialization of oncology therapeutics, including novel combinations.
  • Clinical outcomes are tracked with specific endpoints: Reported clinical metrics include Median Overall Survival (Primary Refractory Patients) and Complete Remission Rate at the End of Induction (Independent Endpoint Review Committee).

Bear case

  • No collaboration and licensing revenue in the latest quarter: For the quarter ended 2026-03-31, Revenue from Collaborations and Licensing Agreements is 0.0B.
  • Operating results reflect heavy losses: Operating margin for the quarter ended 2026-03-31 is -2380.1%.
  • Safety and tolerability appear challenging in reported clinical data: Reported rates include Serious Treatment-Emergent Adverse Event Rate of 35.9% and Grade 3 or Higher Treatment-Emergent Adverse Event Rate of 85.9%.
Valuation — source: SEC EDGAR (first-party)
Price$17.19
Market Cap$638.50M
Price / Book3.91
Price / Sales307.27
FCF Yield-7.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$10.84M
Net Margin-1419.6%
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)1.7%
FCF Growth (YoY)-10.9%
Financial Health — source: SEC EDGAR
Altman Z-Score5.57 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($75.93M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua T. Brumm
Employees41
CountryUS
IPO Date2014-01-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Assembly Biosciences, Inc. (ASMB)
  • Sensei Biotherapeutics, Inc. (SNSE)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • CorMedix Inc. (CRMD)
  • Arvinas, Inc. (ARVN)
  • Verastem, Inc. (VSTM)
  • Altimmune, Inc. (ALT)
  • Aquestive Therapeutics, Inc. (AQST)
CBIO earnings history · CBIO institutional & insider holders · CBIO KPIs & operating metrics · CBIO financials · CBIO investor presentations & press releases · CBIO SEC filings · CBIO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.